Liglinra (Linagliptin)

Linagliptin blocks the DPP‑4 enzyme, which normally breaks down the incretin hormones GLP‑1 and GIP. By inhibiting this enzyme, linagliptin raises endogenous incretin levels, enhancing glucose‑dependent insulin secretion and suppressing glucagon release, which together lower blood glucose concentrations.

The specific dose of Liglinra is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal and hepatic function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for linagliptin during pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Liglinra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Liglinra (linagliptin) shares the same class mechanism as other DPP‑4 inhibitors but is distinguished by its primarily non‑renal elimination, which means dose adjustment is generally not required in patients with renal impairment, unlike some alternatives that require renal dosing modifications.

Liglinra should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Liglinra is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious but rare risks include pancreatitis, severe hypersensitivity reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, bullous pemphigoid, hepatic injury, angioedema, and anaphylactic shock. Patients should seek immediate medical attention if they experience symptoms suggestive of these conditions.

Liglinra should be avoided in patients with a known hypersensitivity to linagliptin or any of its excipients. Caution is also advised for individuals with a history of pancreatitis, severe hepatic disease, or those taking medications that may cause dangerous drug interactions as listed in the prescribing information.